濮阳东方医院男科治阳痿很便宜濮阳东方男科价格收费低,濮阳东方妇科口碑比较好,濮阳东方男科医院技术很好,濮阳东方医院看妇科技术权威,濮阳东方医院割包皮比较好,濮阳东方医院治疗阳痿口碑好收费低,濮阳东方妇科医院做人流口碑比较好

SAN FRANCISCO, April 5 (Xinhua) -- Apple Inc.'s iPad 2 has topped the ratings by Consumer Reports, an influential U.S. magazine for product reviews, in the latest tests of the 10 most- promising tablet computers.According to the ratings released on Tuesday, the Apple iPad 2 with Wi-Fi plus 3G (32G), which is priced at 730 U.S. dollars, topped the ratings, scoring "excellent" in nearly every category.Besides several models from Apple, other brands tested include Archos, Dell, Motorola, Samsung and Viewsonic. Each tablet was evaluated on 17 criteria, including touch-screen responsiveness, versatility, portability, screen glare and ease of use."So far, Apple is leading the tablet market in both quality and price, which is unusual for a company whose products are usually premium priced," Paul Reynolds, electronics editor at Consumer Reports, said in a statement.The Motorola Xoom, whose price is 800 dollars, stood out as the iPad 2's main rival. It boasts several features that the iPad lacks, including a built-in memory card reader and support for the Flash videos.The first-generation iPad, priced at 580 dollars, also outscored many of the other models tested but tied with the Motorola Xoom, according to tests by Consumer Reports.

BEIJING, March 27 (Xinhua) -- China's search giant Baidu has pledged to remove all unauthorized literary works from its free online literary database Wenku within three days.After receiving requests from copyright owners to remove their works, Baidu has sped up its process of checking for unauthorized items. The unauthorized works were uploaded by Internet users to Wenku without prior approval from the authors, a spokesman for the Chinese search engine giant said in a statement.In the statement issued Saturday, Baidu apologized for what has "hurt the feelings of a certain number of writers" during Wenku's previous stage of operation, according to a report published Sunday by daily newspaper The Beijing News.Baidu said it respects copyright laws and will continue to cooperate with publishers and writers to establish a revenue-sharing model that will ensure that copyright owners receive a share of revenues from online versions of their works.Hailing Baidu's move to remove the unauthorized works, Wang Yefei, deputy head of Beijing Municipal Bureau of Copyrights hopes that Baidu and the publishers should work together to find win-win methods of mutual cooperation, according to the newspaper.However, some writers involved in the copyright row are dissatisfied with remedies Baidu has so far taken.Shen Haobo, CEO of Beijing Motie Book Co. Ltd, one of the six negotiators representing writers in Thursday's negotiations, told the Beijing Youth Daily that Baidu apologized only because of public pressure, but it did not mean to alter its current operation model for Wenku."Without changes in the operation model, the unauthorized works, even if removed now, could be uploaded again sometime later. Besides, it's unacceptable that Baidu reiterated that it had not infringed on our copyright," Shen was quoted as saying.Popular writer and blogger Han Han posted an open letter he wrote to Baidu's CEO Li Yanhong in his blog, indicating that he might take further actions to uphold his rights if Baidu's stance remains unchanged.Baidu's online literary database Wenku is an open platform for online resource sharing. It has been in operation since 2009.More than 40 Chinese writers posted an open letter online on March 15, accusing Baidu of stealing their works and infringing on their copyrights. Baidu's Wenku database was blamed for allowing literary works to become available online without the authors' prior approval.Baidu was asked to make a public apology, compensate for the writers' losses and halt any cases of copyright infringement.

BEIJING, May 24 (Xinhuanet) -- CT scan, a widely used heart-imaging test, is likely to result in the over treatment for patients with heart disease, according to a study published online by the Archives of Internal Medicine on Monday.CT, which produces a detailed image of the heart that reveals cholesterol buildups in the coronary arteries, is widely used in the hospital around the world."Testing might lead to more harm than good," said McEvoy, a doctor at Seoul National University Bundang Hospital in S. Korea.His team led the study, in which 2,000 healthy adults were divided into two groups. One thousand adults had CT scans and another half had standard tests, including routine checks of their blood pressure and cholesterol levels.After 18 months, the 215 people who had worrisome CT scans were advised to have additional tests and medical treatment, and some even advised to have surgery. But less than 10 percent in the group of standard test were reported to need medications.Therefore, physicians cannot easily ignore the diagnoses made by the new imaging techniques, McEvoy said, "We are left with the dilemma of what to do with the results,"According to McEvoy, doctors should focus on patients' lifestyle and traditional risk factors such as smoking and obesity.

WASHINGTON, March 24 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Thursday approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox.After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging."The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease" said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement. ( Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache, according to the FDA.Zostavax, manufactured by Merck & Co., was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.